Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biotech firm Elusys Therapeutics and Pfizer have entered into a research and license agreement to develop new therapeutics for infectious diseases including MRSA, using Elusys' HP antibody technology.
Subscribe to our email newsletter
The research collaboration will include ETI-211, an HP antibody for the treatment of MRSA infections.
Under the terms of the agreement Elusys and Pfizer will collaborate on determining the full product profile of ETI-211 and perform research on other indications of the HP antibody technology. Elusys will receive an upfront equity investment, R&D funding plus near-term research milestones.
“In parallel with the collaborative research on ETI-211, Elusys will continue to advance its other internal clinical development programs. These include Anthim, our phase I therapeutic for anthrax infection and our HIV HP antibody and CR1 Vaccine programs,” commented Elizabeth Posillico, president & CEO of Elusys Therapeutics.
HP antibodies represent a unique approach to the treatment of a variety of infectious diseases by enhancing the effectiveness of the body’s natural defense mechanisms to remove and destroy life-threatening pathogens.
In previously reported studies by Elusys, mice given ETI-211 prophylactically were completely protected against MRSA. Further, all ETI-211 treated animals survived a second lethal challenge of either MRSA or S. epidermidis months later, with no additional drug treatment.